Nintedanib in Progressive Fibrosing Interstitial Lung Diseases Reply

被引：0
作者：
Flaherty, Kevin R. [1 ]
Wells, Athol U. [2 ]
Brown, Kevin K. [3 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Royal Brompton & Harefield NHS Fdn Trust, London, England
[3] Natl Jewish Hlth, Denver, CO USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：781 / 781
页数：1
相关论文
共 4 条
  • [1] Flaherty KR, 2017, BMJ OPEN RESPIR RES, V4, DOI 10.1136/bmjresp-2017-000212
  • [2] Cyclophosphamide versus placebo in scleroderma lung disease
    Tashkin, Donald P.
    Elashoff, Robert
    Clements, Philip J.
    Goldin, Jonathan
    Roth, Michael D.
    Furst, Daniel E.
    Arriola, Edgar
    Silver, Richard
    Strange, Charlie
    Bolster, Marcy
    Seibold, James R.
    Riley, David J.
    Hsu, Vivien M.
    Varga, John
    Schraufnagel, Dean E.
    Theodore, Arthur
    Simms, Robert
    Wise, Robert
    Wigley, Fredrick
    White, Barbara
    Steen, Virginia
    Read, Charles
    Mayes, Maureen
    Parsley, Ed
    Mubarak, Kamal
    Connolly, M. Kari
    Golden, Jeffrey
    Olman, Mitchell
    Fessler, Barri
    Rothfield, Naomi
    Metersky, Mark
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (25) : 2655 - 2666
  • [3] Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
    Torrisi, Sebastiano Emanuele
    Kahn, Nicolas
    Waelscher, Julia
    Sarmand, Nilab
    Polke, Markus
    Lars, Kehler
    Eichinger, Monika
    Heussel, Claus Peter
    Palmucci, Stefano
    Sambataro, Francesca Maria
    Sambataro, Gianluca
    Sambataro, Domenico
    Vancheri, Carlo
    Kreuter, Michael
    [J]. BMC PULMONARY MEDICINE, 2019, 19 (01)
  • [4] What's in a name? That which we call IPF, by any other name would act the same
    Wells, Athol U.
    Brown, Kevin K.
    Flaherty, Kevin R.
    Kolb, Martin
    Thannickal, Victor J.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 51 (05)
1